Why Is Padcev So Hard to Access? [Explained for 2026]

If you or a loved one has been prescribed Padcev (enfortumab vedotin-ejfv), you may have quickly discovered that getting access to this medication isn't simple. Unlike a typical prescription you pick up at your local pharmacy, Padcev is a specialty oncology infusion drug that comes with a unique set of access barriers — from insurance hurdles to the requirement that it be administered at a specialized infusion center.

In this guide, we break down exactly why Padcev can be difficult to access, what the most common obstacles are, and what steps patients and caregivers can take to navigate them in 2026.

What Is Padcev and Why Is It Different From Other Medications?

Padcev is a Nectin-4-directed antibody-drug conjugate (ADC) approved by the FDA for the treatment of locally advanced or metastatic urothelial cancer (bladder cancer and cancers of the urinary tract). It was first approved in December 2019 and received full approval for use in combination with pembrolizumab (Keytruda) in December 2023.

Unlike oral pills or even standard chemotherapy infusions that many cancer centers stock routinely, Padcev is a high-cost biologic that requires:

Intravenous infusion over 30 minutes in a clinical setting

Specialty oncology prescribers (typically medical or urologic oncologists)

A hospital or outpatient infusion center equipped to handle hazardous oncology drugs

Insurance pre-authorization and often specialty pharmacy coordination

Why Does Prior Authorization Create Access Delays?

Prior authorization (PA) is one of the most common reasons patients face delays getting Padcev. Because each vial of Padcev costs approximately $2,793 for the 20 mg size and $4,185 for the 30 mg size — and a single treatment cycle can cost over $17,000 — insurers routinely require detailed clinical documentation before approving coverage.

Your oncologist's office typically handles PA submissions, but the process can take days to weeks. Common reasons PA is denied or delayed include:

Missing pathology or biomarker documentation

Incomplete prior treatment history (step therapy requirements)

Incorrect J-code billing (J9177 for Padcev — 1 unit = 0.25 mg)

Plan-specific formulary restrictions or non-coverage determinations

The PADCEV Support Solutions program (1-888-402-0627) can help navigate the PA process and appeal denials on your behalf.

Why Is Padcev Only Available at Specialty Centers?

Padcev is classified as a hazardous drug and must be handled and disposed of using special procedures. It cannot be dispensed at a retail pharmacy or self-administered at home. Patients must receive each dose at a hospital infusion center, outpatient cancer center, or specialty infusion suite.

This means that patients in rural areas or regions with fewer oncology centers may face longer travel times, scheduling delays, or difficulty finding a center that stocks Padcev and has experience administering it.

What Role Does the Medical Benefit Play vs. the Pharmacy Benefit?

Padcev is typically billed under the medical benefit (not the pharmacy benefit), using HCPCS code J9177. This distinction matters because patients who have strong pharmacy coverage may be surprised to find their pharmacy plan doesn't apply to Padcev. Your oncology team's billing staff should be familiar with medical benefit billing for infused oncology drugs.

For patients with Medicare, coverage typically falls under Part B (outpatient medical) rather than Part D (prescription drugs), which has different cost-sharing implications.

39,483+ patients found their medications in stock

39K+

Find Padcev In Stock Today →

Are There Cost Assistance Programs for Padcev?

Yes. Astellas offers two major assistance pathways for Padcev:

PADCEV Copay Assistance Program: Eligible commercially insured patients may pay as little as $5 per dose, with a maximum of $25,000 in annual copay assistance. Not available to Medicare/Medicaid patients.

PADCEV Patient Assistance Program (PAP): Provides Padcev at no cost to uninsured patients who meet financial eligibility requirements.

Is Padcev in Shortage in 2026?

As of 2026, Padcev is not on the FDA drug shortage list. However, because it is a high-cost biologic that must be ordered and stocked by specialty infusion centers, some centers may have limited quantities on hand or may need to order it ahead of your appointment. Your oncology team typically coordinates this in advance.

The main access challenges for Padcev in 2026 are not about drug supply, but about insurance coverage, PA approvals, and access to specialized infusion centers.

Skip the calls, skip the stress.

Find Padcev In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

How Can medfinder Help?

medfinder helps patients find which pharmacies and infusion centers near them can fill or administer their prescribed medications. If you've been told your oncology center doesn't have Padcev in stock or you're struggling to find a facility near you, medfinder contacts facilities on your behalf and texts you results — so you spend less time calling around and more time focused on your health.

Learn more in our guide: How to Find Padcev in Stock Near You (Tools + Tips).

Key Takeaways

Padcev is not a retail pharmacy drug — it's an IV infusion administered at cancer/infusion centers

Insurance prior authorization is the #1 access barrier for most patients

PADCEV Support Solutions (1-888-402-0627) provides PA support, copay assistance, and patient assistance for eligible patients

Padcev is not in FDA shortage — access challenges are primarily administrative and geographic

medfinder can help locate facilities near you that can administer Padcev